VeraSun Invests in Company Working on Cellulosic Ethanol Production

VeraSun Energy Corporation, one of the nation’s largest ethanol producers, today announced it has made a minority investment in SunEthanol, a Massachusetts-based company working to commercialize proprietary cellulosic ethanol production technology. SunEthanol currently has a patent-pending process that consolidates multiple steps into one efficient and naturally-occurring process utilizing a variety of agricultural feed stocks to produce ethanol.

“SunEthanol has unique technology that if proven to be commercially feasible will be a positive step forward for cellulosic ethanol.” said Bill Honnef, VeraSun Senior Vice President, Sales and Marketing. “While we believe corn-based ethanol production will continue to play a key role in our industry long into the future, ethanol from cellulosic feedstocks will complement corn-based ethanol in meeting the growing global demand for renewable fuels. We continue to evaluate technologies that have the potential to efficiently convert cellulose to biofuels.”

SunEthanol was recently formed by a team of entrepreneurs in Amherst, Mass. The company’s patent-pending, consolidated bio-processing (CBP) technology is being tested on multiple feedstocks. Dr. Susan Leschine is a company founder and the Chief Scientist at SunEthanol. Leschine originally discovered the unique CBP technology.

“We are delighted to have one of the nation’s leading producers of ethanol as an investor,” said Jef Sharp, SunEthanol’s CEO. “Together, we hope to help shape the nation’s cellulosic ethanol future. We believe there are strong synergies between our two organizations that will enable us to accelerate the pace of commercialization of this new technology.”

In addition to VeraSun’s investment, SunEthanol also secured financing for the development of its technology through Battery Ventures. Battery Ventures has been investing in technology and innovation worldwide since 1983 and currently manages approximately $3 billion in committed capital.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.